Verrica Pharmaceuticals (VRCA) EPS (Basic) Growth (3y) (2020 - 2026)
Verrica Pharmaceuticals (VRCA) EPS (Basic) Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | -38.31% |
| 10 | Verrica Pharmaceuticals | 105.87 Mn | 94.67 Mn | - | 36.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.23% |
| Mar 31, 2026 | 41.96% |
| Dec 31, 2025 | 19.20% |
| Sep 30, 2025 | -184.18% |
| Jun 30, 2025 | 26.11% |
| Mar 31, 2025 | 30.04% |
| Dec 31, 2024 | 14.02% |
| Sep 30, 2024 | -12.30% |
| Jun 30, 2024 | 17.39% |
| Mar 31, 2024 | -693.07% |
| Dec 31, 2023 | -0.89% |
| Sep 30, 2023 | -3.27% |
| Jun 30, 2023 | 23.91% |
| Mar 31, 2023 | 24.30% |
| Dec 31, 2022 | 15.56% |
| Sep 30, 2022 | 26.05% |
| Jun 30, 2022 | 10.89% |
| Mar 31, 2022 | 14.93% |
| Dec 31, 2021 | 8.73% |
| Sep 30, 2021 | 12.70% |